GlassScriptPhysician profile
Adekemi A Harvey
NPI 1770803504
$4,784.93
in general payments reported to CMS, 2019-2025
36 companies · $748 in 2025
The $748 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $288 · 2021: $284 · 2022: $826 · 2023: $806 · 2024: $583 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.53 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $585.24 | 2019-2025 | Aklief, Epsolay, Oracea |
| Janssen Biotech, INC. | $569.64 | 2019-2025 | Tremfya |
| Abbvie INC. | $541.88 | 2019-2025 | Botox, Rinvoq |
| Novartis Pharmaceuticals Corporation | $326.83 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $258.22 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $209.43 | 2019-2024 | Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $181.32 | 2019-2025 | Arazlo, Jublia, Duobrii |
| Pfizer INC. | $175.52 | 2019-2023 | |
| Lilly USA, LLC | $170.48 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Incyte Corporation | $165.34 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $164.56 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $157.89 | 2022-2023 | Dupixent |
| Celgene Corporation | $143.87 | 2019 | |
| Leo Pharma INC. | $137.67 | 2019-2025 | Anzupgo |
| Allergan, INC. | $92.08 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $91.06 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $83.77 | 2022-2024 | Otezla |
| Almirall LLC | $75.69 | 2019-2022 | |
| Organon LLC | $73.69 | 2024-2025 | Vtama |
| Epi Health, LLC | $67.33 | 2020-2022 | |
| Genzyme Corporation | $65.87 | 2022-2023 | |
| Dermavant Sciences, INC. | $54.95 | 2024 | Vtama |
| Journey Medical Corporation | $52.84 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $51.73 | 2025 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $47.62 | 2023-2025 | Zoryve |
| Aclaris Therapeutics, INC. | $37.11 | 2019 | |
| Lnhc, INC | $28.78 | 2025 | Zelsuvmi |
| Vyne Pharmaceuticals INC. | $27.19 | 2020-2021 | |
| Blueprint Medicines Corporation | $23.07 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2024 | Spevigo |
| Botanix Sb INC | $20.46 | 2025 | Sofdra |
| Dermira, INC. | $20.18 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.79 | 2020 | |
| Mission Pharmacal Company | $16.69 | 2019 | |
| Kyowa Kirin, INC. | $13.02 | 2021 | |
| Prugen, INC. Pharmaceuticals | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adekemi Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.